AnGes, Inc.
4563.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.45B
Close$
Share Statistics
| Market cap | $13.45 Billion |
|---|---|
| Enterprise Value | $13.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-14.44 |
| Beta | 0.57 |
| Outstanding Shares | 397,365,385 |
Return
| Return on Equity | -1898.81% |
|---|---|
| Return on Assets | -106.70% |
| Return on Invested Capital | -617.11% |
Valuation & Multiples
| P/E Ratio | -3.57 |
|---|---|
| PEG | -0.04 |
| Price to Sales | 17.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.4 |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 3.52 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AnGes, Inc.
56 employees
CEO: Ei Yamada AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor...